| DC21718 |
T-3364366 |
A potent, selective and orally available inhibitor of delta-5 desaturase (D5D) with Ki of <2.7 nM and IC50 of 19 nM, with excellent selectivity over D6D and SCD. |
|
| DC20768 |
Tonapofylline |
A potent, selective and orally bioavailable adenosine A1 (A1A) receptor antagonist with Ki of 7 nM. |
|
| DC22682 |
INCB9471 |
A potent, selective and orally bioavailable CCR5 antagonist IC50 of 6.5 nM, Kd of 3.1 nM in human PBMCs. |
|
| DC23643 |
JNJ 54166060 |
A potent, selective and orally bioavailable P2X7 receptor with IC50 of 4 nM and 115 nM for hP2X7 and rP2X7, respectively. |
|
| DC21600 |
S1P Lyase inhibitor 31 |
A potent, selective and orally bioavailable S1P lyase (S1PL) inhibitor with enzyme IC50 of 44 nM, cell IC50 of 110 nM. |
|
| DC23207 |
JNJ-17203212
Featured
|
A potent, selective and orally bioavailable TRPV1 receptor antagonist with IC50 of 65 nM and 102 nM for hTRPV1 and rTRPV1, respectively. |
|
| DC21464 |
Eribaxaban |
A potent, selective and orally efficacious factor Xa (FXa) inhibitor with IC50 of 0.32 nM. |
|
| DC25047 |
Calphostin C |
A potent, selective and photo-dependent inhibitor of PKC with IC50 of 50 nM. |
|
| DC20602 |
5F 203
Featured
|
A potent, selective antitumour agent through activation the aryl hydrocarbon receptor (AhR) pathway. |
|
| DC21576 |
RO-5508887 |
A potent, selective BACE inhibitor with IC50 of 30 nM for BACE1, equally potent against BACE2 (IC50=40 nM) but >1,000-fold selectivity over cathepsin D, cathepsin E, pepsin and renin. |
|
| DC21103 |
GW405833 hydrochloride |
A potent, selective cannabinoid receptor CB2 agonist with Ki of 3.6 nM, 1200-fold selectivity over CB1. |
|
| DC20658 |
AM1241
Featured
|
A potent, selective cannabinoid receptor CB2 agonist with Ki of 7.1 nM, >80-fold selectivity over CB1 receptors in radioligand binding assay. |
|
| DC21376 |
NESS-0327 |
A potent, selective CB1 cannabinoid receptor antagonist with Ki of 350 fM, >60,000-fold selective for the CB1 receptor versus CB2 receptor (Ki=21 nM). |
|
| DC23357 |
CBP bromodomain inhibitor |
a potent, selective CBP bromodomain inhibitor with IC50 of 69 nM, displays exquisite selectivity over BRD4(1) (IC50=18 uM) and the broader bromodomain family.. |
|
| DC22697 |
PF-04756956 |
A potent, selective CCK1 receptor agonist with EC50 of 0.47 nM. |
|
| DC21393 |
nNOS-IN-25 |
A potent, selective cell permeable neuronal nitric oxide synthase (nNOS) inhibitor with Ki of 30 nM. |
|
| DC20633 |
ACG-548B |
A potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 0.12 uM, >400-fold selectivity over ChoKβ. |
|
| DC20632 |
ACG-416B |
A potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 0.13 uM, >385-fold selectivity over ChoKβ. |
|
| DC21741 |
RSM-932A |
A potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.0 uM, 33-fold selectivity over ChoKβ. |
|
| DC22917 |
SCH 79797 dihydrochloride
Featured
|
A potent, selective competitive and nonpeptide PAR-1 antagonist with IC50 of 70 nM. |
|
| DC20580 |
Vitacoxib |
A potent, selective COX-2 inhibitor with IC50 of 0.34 ug/mL, >50-fold selectivity over COX-1 (IC50=19.4 ug/mL). |
|
| DC22418 |
CCX-771 |
A potent, selective CXCR7 antagonist with IC50 of 4.1 nM. |
|
| DC22912 |
SCH39166 |
A potent, selective D1 dopamine receptor antagonist with Ki of 3.6 nM, >300-fold selectivity over D2 and 5-HT2 receptors. |
|
| DC22910 |
ABT-724 |
A potent, selective dopamine D4 receptor agonist that activates human dopamine D4 receptors with EC50 of 12.4 nM, with no effect on dopamine D1, D2, D3, or D5 receptors. |
|
| DC22909 |
ABT-724 trihydrochloride |
A potent, selective dopamine D4 receptor agonist that activates human dopamine D4 receptors with EC50 of 12.4 nM, with no effect on dopamine D1, D2, D3, or D5 receptors. |
|
| DC22586 |
AZD9496 maleate |
A potent, selective estrogen receptor downregulator (SERD) with ER downregulation pIC50 of 9.68. |
|
| DC20378 |
FABP4 inhibitor 1 |
A potent, selective FABP4 inhibitor with Ki of 30 nM.. |
|
| DC22881 |
GLP1-agonist-1 |
A potent, selective GLP-1 agonist. |
|
| DC20392 |
GLUT4-IN-17 |
A potent, selective glucose transporter 4 (GLUT4) inhibitor with IC450 of 10.8 uM, inhibits MM cell proliferation. |
|
| DC22747 |
AICP
Featured
|
AICP is a highly potent and selective GluN2C-containing NMDA receptor agonist that specifically targets the glycine-binding site of these receptors. It exhibits an EC50 of 1.7 nM at GluN1/GluN2C NMDA receptors, making it a powerful tool for studying the functional roles of GluN2C-containing NMDA receptors in the central nervous system. |
|
